Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic and Cell and Gene Therapy Markets

SOMERSET, N.J., Jan. 11, 2022 /PRNewswire-PRWeb/ -- Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

Work has been undertaken at the facility to expand the packaging area by around 20,000 square feet and includes the addition of seven new temperature-controlled processing suites, which can operate at either refrigerated or frozen conditions to precisely match the needs of the drugs being handled. Further ambient space has also been added for packaging operations and materials storage.

The new suites include full serialization capabilities, specifically designed for small-scale batches of commercial products. Validation of the equipment is expected to be completed by the end of Q1 2022.

"Advanced therapeutics require increasingly complex handling requirements, and the investment we have made in Philadelphia allows Catalent to operate efficient packaging processes and operations, bridging the gap between clinical scale and niche commercial volumes," commented Ann McMahon, General Manager of Commercial & Integrated Development Operations at Catalent Clinical Supply Services. "The specifically designed packaging areas not only provide optimal commercial opportunities for drug developers, but also the safest working conditions for employees in terms of air exchange rates, carbon dioxide monitoring, and ultraviolet air sanitization."

The 200,000 square-foot Philadelphia facility is the largest site in Catalent's global clinical supply network and the company's North American Center of Excellence for clinical supply packaging. It includes an on-site pharmacy to support FlexDirect® direct-to-patient services for clinical trials, as well as access to Catalent's FastChain® demand-led supply services, primary and secondary packaging capabilities, a range of temperature options for storage and distribution, and clinical returns and destruction services.

About Catalent
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products to over 1,000 customers annually.

Catalent's expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Media Contact

Chris Halling, Catalent, +447580041073, [email protected]

Richard Kerns, Northern Exposure Public Relations, +441617285880, [email protected]

SOURCE Catalent